High efficacy of adefovir and entecavir combination therapy in patients with nucleoside-refractory hepatitis B
Open Access
- 1 January 2012
- journal article
- Published by The Korean Association for the Study of the Liver in Clinical and Molecular Hepatology
- Vol. 18 (1) , 75-83
Abstract
Newly developed and potent antiviral agents suffer from the problem of drug resistance. Multidrug resistance is a major impediment in the treatment of patients with chronic hepatitis B (CHB). In line with American Association for the Study of Liver Diseases guidelines, adefovir dipivoxil (ADV) add-on therapy is recommended in the case of lamivudine resistance, while tenofovir disoproxil fumarate (TDF) is recommended for ADV or entecavir (ETV) resistance. TDF is currently not available in Korea. ADV+ETV combination therapy may be a viable alternative to TDF in patients with either ADV or ETV resistance. However, the efficacy of ADV+ETV combination therapy in patients with CHB and multidrug resistance is unclear. This study investigated the efficacy of ADV+ETV combination therapy in patients with multidrug resistance. Twenty-five patients were enrolled and were administered ADV+ETV combination therapy for at least 6 months. Blood was drawn at baseline and at 3, 6, 9, and 12 months after commencing treatment, and the following blood parameters were analyzed: alanine transaminase, hepatitis B e-antigen (HBeAg), anti-hepatitis B e-antigen, and hepatitis B virus (HBV) DNA levels. The initial virological response (IVR) was defined as an HBV DNA level of <4 log(10) copies/mL after 6 months of combination therapy. The IVR rate was 76%. The proportion of patients with a high viral load (≥5.0 log) dropped from 76% at baseline to only 5% after 6 months of treatment. The biochemical response rate during the first 6 months was 71%. HBeAg was lost in 2 patients (10%). ADV+ETV combination therapy induced a good IVR in CHB patients who were refractory to more than 2 antiviral agents. This regimen may be a good alternative to TDF in Korea, where that drug is not available.Keywords
This publication has 19 references indexed in Scilit:
- Prediction of the response to peg‐interferon‐alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatmentJournal of Medical Virology, 2010
- Chronic hepatitis B: Update 2009 #Hepatology, 2009
- Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy #Hepatology, 2009
- EASL Clinical Practice Guidelines: Management of chronic hepatitis BJournal of Hepatology, 2009
- Distribution of hepatitis B virus genotypes in KoreaThe Korean Journal of Hepatology, 2009
- Virologic response and resistance to adefovir in patients with chronic hepatitis BJournal of Hepatology, 2006
- Hepatitis B Virus Genotype C Prevails Among Chronic Carriers of the Virus in KoreaJournal of Korean Medical Science, 2005
- [Reappraisal of HBV genotypes and clinical significance in Koreans using MALDI-TOF mass spectrometry].2004
- Hepatitis B Virus Infection — Natural History and Clinical ConsequencesNew England Journal of Medicine, 2004
- Clinical aspects of hepatitis B virus infectionThe Lancet, 1993